HPV genotype distribution and risk factors for cervical dysplasia among HPV-positive women with or without HIV infection in Shanghai, China Authors: Yuxi Ma, Min Liu Published: 2026 ABSTRACT BackgroundHuman papillomavirus (HPV) and human immunodeficiency virus (HIV) co-infection exerts a substantial impact on women’s health globally. This study enrolled confirmed HPV-infected women in Shanghai stratified by HIV status to compare the profiles of HPV genotype distribution and cervical lesions between two groups, and to identify the risk factors for cervical dysplasia among women with HIV-HPV co-infection.MethodsA total of 238 confirmed HPV-infected women who attended the Shanghai Public Health Clinical Center between January 2019 and July 2023 were enrolled in this cross-sectional study. All participants were divided into HIV-positive and HIV-negative groups. We compared the pathological distribution characteristics, high/low-risk HPV infection patterns and cervical cytological abnormalities between the two groups. Multivariate logistic regression was used to explore risk factors for cervical dysplasia in HIV-HPV co-infected women.ResultsAmong the 238 HPV-positive patients, 47.9% (114/238) were HIV-HPV co-infected. The top five predominant HPV genotypes were HPV16, HPV52, HPV58, HPV53, and HPV18. The HIV-positive group had significantly higher rates of HR-HPV infection (χ²=4.537, p = 0.037) and multiple HR-HPV infections (χ²=15.878, p < 0.001) than the HIV-negative group. HPV33 and HPV66 were more prevalent in the HIV-positive group, and the positivity rates of HPV genotypes covered by 2-valent, 4-valent, and 9-valent HPV vaccines were all significantly higher in the HIV-positive group than in the HIV-negative group. HPV52 and HPV58 (13.10%, 11/84) were the most common genotypes in multiple HPV infections. The HIV-positive group had a significantly higher rate of cytological abnormalities (χ²=11.658, p < 0.001). Multivariate logistic regression analysis indicated that HIV RNA load > 1000 copies/µl was an independent risk factor (OR 9.845, 95%CI 1.324–73.202, p = 0.026) for cervical dysplasia in the HIV-positive group.ConclusionsWithin the HPV-positive female population, HIV-positive women exhibit higher burdens of multiple HPV infection and cervical cytological abnormalities. Elevated HIV RNA load is a key independent risk factor for cervical dysplasia in this co-infected population. Immediate initiation of antiretroviral therapy, prioritized 9-valent HPV vaccination, and regular cervical cancer screening are recommended to reduce the risk of cervical lesions and alleviate the disease burden among HIV-HPV co-infected women. Background Cervical cancer is the fourth most common malignant tumor among women worldwide and the fourth leading cause of cancer-related deaths in females [1]. According to the Global Cancer Statistics 2022, approximately 660,000 new cases of cervical cancer were diagnosed and 350,000 deaths attributed to the disease globally, with China accounting for nearly 150,000 new cases and 57,000 deaths [2, 3]. Human papillomavirus (HPV) infection is the primary etiological factor of cervical cancer, with approximately 99% of malignancies attributable to persistent infection with high-risk HPV (HR-HPV) [4]. Based on genetic sequences and evolutionary relationships, HPV has been classified into five genera with more than 200 identified genotypes [5]. Approximately 35 HPV genotypes are associated with genital tract infections, and 20 genotypes are linked to neoplastic lesions. According to carcinogenicity, HPV genotypes are categorized into low-risk HPV (LR-HPV) and HR-HPV: LR-HPV (e.g., 6, 11, 42, 43, 44) usually causes latent infections or benign papillomas and is typically cleared by the host immune system; HR-HPV (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68) is closely associated with the development of cervical cancer [6, 7]. Most HPV infections are spontaneously cleared within 12 to 24 months, but women living with HIV (WLHIV) are more susceptible to persistent HPV infection due to immune deficiency [8]. HIV infection induces severe immunosuppression characterized by CD4 + T cell depletion, which impairs the host’s ability to mount an effective immune response to HPV [9]. Consequently, HIV-positive women not only have a higher risk of persistent HPV infection but also face a significantly increased risk of high-grade cervical intraepithelial neoplasia (CIN) and invasive cervical cancer. The incidence of cervical cancer in WLHIV is estimated to be six times higher than that in HIV-negative women, leading to a higher disease burden in this population [10]. Over the past two decades, accumulating evidence has confirmed the clinical relevance of HIV-HPV co-infection [11, 12], with an increased risk of HPV-associated malignancies reported in HIV-infected individuals [13, 14]. However, studies on risk factors for cervical lesions in women with HIV-HPV co-infection remain limited, especially the lack of large-scale, multicenter cohort data in low- and middle-income countries (LMICs), where the burdens of both HIV and HPV infections are substantial [15]. China, as an LMIC with a growing HIV epidemic and high HPV infection rate, lacks targeted clinical data on HIV-HPV co-infection in women. Therefore, this study enrolled HPV-infected women in Shanghai to compare the distribution of HPV genotypes and cervical lesions between HIV-positive and HIV-negative groups, and to identify the risk factors for cervical dysplasia among HIV-positive women. These findings provide insights into the clinical management of HIV-HPV co-infection and lay a foundation for developing targeted prevention and treatment strategies for this high-risk population. Methods Study design and study population A cross-sectional study was conducted using data from the cervical cancer screening program at the Shanghai Public Health Clinical Center, China. Inclusion criteria: (1) women aged ≥ 18 years who were hospitalized or attended the outpatient clinic from January 2019 to July 2023; (2) confirmed HPV-positive results by HPV genotyping; (3) complete medical records, including Thinprep cytologic test (TCT) and subsequent pathological examination; (4) completed HIV antibody and HIV RNA load tests. Exclusion criteria: (1) acute or chronic vaginitis; (2) pregnancy or lactation; (3) other systemic malignant tumors; (4) incomplete clinical or laboratory data. All participants provided written informed consent for clinical examination and data collection. This study was approved by the Ethics Committee of the Shanghai Public Health Clinical Center. Data collection Demographic and clinical data Demographic and clinical data were extracted from the Clinical Information System 5.6 of the Shanghai Public Health Clinical Center, including age, marital status, reproductive history (menopause, gravidity, parity), and history of other infectious diseases (syphilis, hepatitis B virus [HBV], hepatitis C virus [HCV]). HIV-related indicators were also collected, including CD4 + T cell count, HIV RNA load, and duration of antiretroviral therapy (ART). Cervical cytology and pathological examination After exposing the cervix, a sampling brush was inserted into the cervical canal and rotated 360° to collect cervical secretions and exfoliated cells, which were immediately placed in liquid-based cytology preservative and sent for testing. Cervical cytological results were interpreted according to the Bethesda System and classified into the following categories: negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of unknown significance (ASC-US), atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion (ASC-H), low-grade squamous intraepithelial lesion (LSIL), high-grade squamous intraepithelial lesion (HSIL), squamous cell carcinoma (SCC), and adenocarcinoma in situ (AIS). HPV genotyping detection HPV genotyping was performed at the Clinical Laboratory of the Shanghai Public Health Clinical Center using the HPV GenoArray Test Kit (BoHui Ltd., Beijing, China). A total of 24 HPV genotypes were detected, including 14 HR-HPV genotypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68) and 10 LR-HPV genotypes (6, 11, 42, 43, 44, 53, 73, 81, 82, 83). Definition: Single HPV infection was defined as infection with one HPV genotype; multiple HPV infection was defined as infection with two or more HPV genotypes; vaccine-type HPV infection was defined as infection with HPV genotypes covered by 2-valent (16, 18), 4-valent (6, 11, 16, 18), or 9-valent (6, 11, 16, 18, 31, 33, 45, 52, 58) HPV vaccines. Statistical analysis All statistical analyses were performed using SPSS 25.0 (IBM Corp., Armonk, NY, USA) and GraphPad Prism 9.0 (GraphPad Software, Inc., La Jolla, CA, USA). Descriptive statistics were used to summarize clinical characteristics: categorical variables were presented as frequencies and percentages, and continuous variables were presented as medians with interquartile ranges (IQR). The Pearson’s χ² test or Fisher’s exact test was used to compare categorical variables between the two groups. The Student’s t-test was used to compare normally distributed continuous variables. Missing data were handled via multiple imputation. Multi-collinearity was evaluated using tolerance and variance inflation factor, with no significant multicollinearity detected among included variables. Logistic regression analysis was used to identify independent risk factors for cervical cytological abnormalities in the HIV-positive group, with adjusted odds ratios (OR) and 95% confidence intervals (95% CI) calculated. Model fit was assessed using the Hosmer-Lemeshow test. A two-sided p-value < 0.05 was considered statistically significant. Results Baseline characteristics of the study population A total of 238 HPV-infected women were enrolled, including 114 (47.9%) in the HIV-positive group and 124 (52.1%) in the HIV-negative group. The median age of all participants was 46 years (IQR: 37–55), with the HIV-positive group significantly younger than the HIV-negative group (44 years [IQR: 35–54] vs. 49 years [IQR: 39–55], t = 2.082, p = 0.038). The HIV-positive group had a significantly higher proportion of divorced/widowed/single participants than the HIV-negative group (17.5% vs. 4.8%, χ²=9.853, p = 0.002). No significant differences were observed in menopause status, parity, or the prevalence of syphilis, HBV, or HCV infection between the two groups (all p > 0.05) (Table 1). For the HIV-positive group, the median duration of HIV infection was 2 years (IQR: 0–7). The CD4 + T cell count was < 200 cells/µl in 14.0% (16/114) of participants, 200–500 cells/µl in 55.3% (63/114), and > 500 cells/µl in 30.7% (35/114). The HIV RNA load was < 20 copies/µl in 49.1% (56/114), 20–1000 copies/µl in 6.1% (7/114), and > 1000 copies/µl in 24.6% (28/114); HIV RNA load was unknown in 20.2% (23/114) of participants. A total of 78.1% (89/114) of HIV-positive participants received ART, including 18.4% (21/114) with ART duration < 12 months and 59.6% (68/114) with ART duration ≥ 12 months. Regarding partner HIV status, 27.2% (31/114) of participants had an HIV-positive partner, 45.6% (52/114) had an HIV-negative partner, and 27.2% (31/114) had an unknown partner status (Table 2). Table 1Baseline characteristics of the study population (n = 238)CharacteristicsTotal(n = 238)HIV-negative(n = 124)HIV-positive(n = 114)Test statisticp-valueAge (Years): Median (IQR)46(37–55)49(39–55)44(35–54)2.0820.038 aMarital status, n (%)9.8530.002 bMarried212(89.1)118(95.2)94(82.5)Divorced/Widow/Single26(10.9)6(4.8)20(17.5)Menopause, n (%)0.4780.490 bYes91(38.2)50(40.3)41(36.0)No147(61.8)74(59.7)73(64.0)Parity, n (%)1.1250.289 b≤ 2123(51.7)60(48.4)63(55.3)> 2115(48.3)64(51.6)51(44.7)Other infectious diseases, n (%)Syphilis6(2.5)1(0.8)5(4.4)1.8110.178 bHBV7(2.9)1(0.8)6(5.3)2.7190.100 bHCV3(1.3)0(0.0)3(2.6)-0.108 ca: Student’s t test, b: Pearson’s chi-square test, c: fisher’s exact test. HBV: hepatitis B virus; HCV: hepatitis C virus; IQR: interquartile range Table 1Baseline characteristics of the study population (n = 238)CharacteristicsTotal(n = 238)HIV-negative(n = 124)HIV-positive(n = 114)Test statisticp-valueAge (Years): Median (IQR)46(37–55)49(39–55)44(35–54)2.0820.038 aMarital status, n (%)9.8530.002 bMarried212(89.1)118(95.2)94(82.5)Divorced/Widow/Single26(10.9)6(4.8)20(17.5)Menopause, n (%)0.4780.490 bYes91(38.2)50(40.3)41(36.0)No147(61.8)74(59.7)73(64.0)Parity, n (%)1.1250.289 b≤ 2123(51.7)60(48.4)63(55.3)> 2115(48.3)64(51.6)51(44.7)Other infectious diseases, n (%)Syphilis6(2.5)1(0.8)5(4.4)1.8110.178 bHBV7(2.9)1(0.8)6(5.3)2.7190.100 bHCV3(1.3)0(0.0)3(2.6)-0.108 ca: Student’s t test, b: Pearson’s chi-square test, c: fisher’s exact test. HBV: hepatitis B virus; HCV: hepatitis C virus; IQR: interquartile range Baseline characteristics of the study population (n = 238) a: Student’s t test, b: Pearson’s chi-square test, c: fisher’s exact test. HBV: hepatitis B virus; HCV: hepatitis C virus; IQR: interquartile range Table 2HIV-related clinical characteristics of the HIV-positive group (n = 114)HIV-related metricsHIV-positive(n = 114)HIV infection time (years): Median (IQR)2(0–7)CD4 + counts (cells/µl), n (%)< 20016(14.0)200–500> 50063(55.3)35(30.7)HIV viral load (copies/µl), n (%)< 2056(49.1)20-1000> 10007(6.1)28(24.6)Unknown23(20.2)Antiretroviral treatment, n (%)Not on ART25(21.9)On ARTART duration < 1221(18.4)ART duration ≥ 1268(59.6)Partner HIV status, n (%)HIV-positive31(27.2)HIV-negative52(45.6)Unknown31(27.2)*IQR: interquartile range; ART: antiretroviral therapy Table 2HIV-related clinical characteristics of the HIV-positive group (n = 114)HIV-related metricsHIV-positive(n = 114)HIV infection time (years): Median (IQR)2(0–7)CD4 + counts (cells/µl), n (%)< 20016(14.0)200–500> 50063(55.3)35(30.7)HIV viral load (copies/µl), n (%)< 2056(49.1)20-1000> 10007(6.1)28(24.6)Unknown23(20.2)Antiretroviral treatment, n (%)Not on ART25(21.9)On ARTART duration < 1221(18.4)ART duration ≥ 1268(59.6)Partner HIV status, n (%)HIV-positive31(27.2)HIV-negative52(45.6)Unknown31(27.2)*IQR: interquartile range; ART: antiretroviral therapy HIV-related clinical characteristics of the HIV-positive group (n = 114) 200–500 > 500 63(55.3) 35(30.7) 20-1000 > 1000 7(6.1) 28(24.6) *IQR: interquartile range; ART: antiretroviral therapy Distribution of HPV genotypes in the two groups Among all 238 participants, 92.4% (220/238) had HR-HPV infection. The top five most common HR-HPV genotypes were HPV16 (37.0%, 88/238), HPV52 (20.2%, 48/238), HPV58 (15.1%, 36/238), HPV53 (13.0%, 31/238), and HPV18 (12.6%, 30/238) (Fig. 1). The positivity rates of HPV33 and HPV66 were significantly higher in the HIV-positive group, HPV33 accounted for 10.5% (12/114) in HIV-positive women versus 3.2% (4/124) in HIV-negative women, HPV66 also accounted for 10.5% (12/114) versus 3.2% (4/124) (χ²=5.048, p = 0.025) (Fig. 1). The HIV-positive group had a significantly lower rate of single HPV infection (40.4% vs. 66.1%, χ²=15.878, p < 0.001) and a significantly higher rate of multiple HPV infection (59.6% vs. 33.9%, χ²=15.878, p < 0.001) than the HIV-negative group. The rate of quadruple or more HPV infections was significantly higher in the HIV-positive group (16.7% vs. 4.0%, χ²=10.457, p = 0.001). The HIV-positive group also had significantly higher rates of LR-HPV infection (38.6% vs. 25.0%, χ²=5.088, p = 0.024), HR-HPV infection (96.5% vs. 89.5%, χ²=4.357, p = 0.037), and multiple HR-HPV infections (48.2% vs. 23.4%, χ²=16.071, p < 0.001) (Table 3). Regarding vaccine-type HPV infection, the positivity rates of genotypes covered by 2-valent (55.3% vs. 41.1%, χ²=4.755, p = 0.029), 4-valent (60.5% vs. 42.7%, χ²=7.519, p = 0.006), and 9-valent (87.7% vs. 71.8%, χ²=9.236, p = 0.002) HPV vaccines were all significantly higher in the HIV-positive group (Table 3). In multiple HPV infections, the most common genotype combination was HPV52 + HPV58 (13.10%, 11/84), followed by HPV16 + HPV56 (11.90%, 10/84) and HPV16 + HPV52 (9.52%, 8/84). HPV52 + HPV58 was also the most frequent combination in the HIV-positive group (14.55%, 8/55) (Table 4; Fig. 2). Fig. 1Distribution of HR-HPV types among HIV-positive and HIV-negative women. HR-HPV, high-risk human papillomavirus Distribution of HR-HPV types among HIV-positive and HIV-negative women. HR-HPV, high-risk human papillomavirus Table 3Distribution of HPV infection types in the two groupsHIV-positive, n (%)HIV-negative, n (%)χ2p-valueª Any HPV infection single infection46(40.4)82(66.1)15.878 < 0.001 Multiple HPV infection 68(59.6)42(33.9)15.878 < 0.001 double infection32(28.1)28(22.6)0.9490.330triple infection17(14.9)9(7.3)3.5760.059quadruple or more infection19(16.7)5(4.0)10.457 0.001 LR-HPV infection Any infection44(38.6)31(25.0)5.088 0.024 Multiple infection8(7.0)5(4.0)1.0250.311 HR-HPV infection Any infection110(96.5)111(89.5)4.357 0.037 Multiple infection55(48.2)29(23.4)16.071 < 0.001 Prophylactic vaccine type Any 2-valent vaccine types63(55.3)51(41.1)4.755 0.029 Any 4-valent vaccine types69(60.5)53(42.7)7.519 0.006 Any 9-valent vaccine types100(87.7)89(71.8)9.236 0.002 a: Pearson’s Chi-square test. *LR-HPV: low-risk HPV; HR-HPV: high-risk HPV Table 3Distribution of HPV infection types in the two groupsHIV-positive, n (%)HIV-negative, n (%)χ2p-valueª Any HPV infection single infection46(40.4)82(66.1)15.878 < 0.001 Multiple HPV infection 68(59.6)42(33.9)15.878 < 0.001 double infection32(28.1)28(22.6)0.9490.330triple infection17(14.9)9(7.3)3.5760.059quadruple or more infection19(16.7)5(4.0)10.457 0.001 LR-HPV infection Any infection44(38.6)31(25.0)5.088 0.024 Multiple infection8(7.0)5(4.0)1.0250.311 HR-HPV infection Any infection110(96.5)111(89.5)4.357 0.037 Multiple infection55(48.2)29(23.4)16.071 < 0.001 Prophylactic vaccine type Any 2-valent vaccine types63(55.3)51(41.1)4.755 0.029 Any 4-valent vaccine types69(60.5)53(42.7)7.519 0.006 Any 9-valent vaccine types100(87.7)89(71.8)9.236 0.002 a: Pearson’s Chi-square test. *LR-HPV: low-risk HPV; HR-HPV: high-risk HPV Distribution of HPV infection types in the two groups a: Pearson’s Chi-square test. *LR-HPV: low-risk HPV; HR-HPV: high-risk HPV Fig. 2Chord diagram of HPV type correlations in women with multiple infections in two groups, HPV, human papillomavirus Chord diagram of HPV type correlations in women with multiple infections in two groups, HPV, human papillomavirus Table 4Top 5 multiple HPV infection combinations in the study populationMultiple infection combinationTotal,n (%)HIV-positive,n (%)HIV-negative,n (%)HPV52 + HPV5811(13.10)8(14.55)3(10.34)HPV16 + HPV5610(11.90)8(14.55)2(6.89)HPV16 + HPV528(9.52)4(7.27)4(13.79)HPV16 + HPV357(8.33)5(9.10)2(6.89)HPV16 + HPV587(8.33)5(9.10)2(6.89) Table 4Top 5 multiple HPV infection combinations in the study populationMultiple infection combinationTotal,n (%)HIV-positive,n (%)HIV-negative,n (%)HPV52 + HPV5811(13.10)8(14.55)3(10.34)HPV16 + HPV5610(11.90)8(14.55)2(6.89)HPV16 + HPV528(9.52)4(7.27)4(13.79)HPV16 + HPV357(8.33)5(9.10)2(6.89)HPV16 + HPV587(8.33)5(9.10)2(6.89) Top 5 multiple HPV infection combinations in the study population Distribution of cervical cytological results by HIV status The overall rate of abnormal cervical cytology (excluding NILM) was 63.4% (151/238) in all participants. The HIV-positive group had a significantly higher rate of abnormal cytological results than the HIV-negative group (74.6% vs. 53.2%, χ²=11.658, p < 0.001) (Table 5). The most common abnormal cytological result in the HIV-positive group was HSIL (27.2%, 31/114), followed by ASC-US (22.8%, 26/114) and LSIL (14.9%, 17/114). Notably, all cases of SCC (7.0%, 8/114) were in the HIV-positive group, with a significant difference between the two groups (p = 0.002). No significant differences were observed in the rates of ASC-US, ASC-H, LSIL, or AIS between the two groups (all p > 0.05) (Table 5). Table 5Distribution of cervical cytological results in the two groups (n = 238)CytologyTotal,n (%)HIV-positive,n (%)HIV-negative,n (%)χ2p-valueNILM87(36.6)29(25.4)58(46.8)11.658 < 0.001 a ASCUS52(21.8)26(22.8)26(21.0)0.1180.732aASCH6(2.5)3(2.6)3(2.4)0.0001.000aLSIL37(15.5)17(14.9)20(16.1)0.0670.796aHSIL47(19.7)31(27.2)16(12.9)7.653 0.006 a AIS1(0.4)01(0.8)-1.000bSCC8(3.4)8(7.0)0- 0.002 b a: Pearson’s chi-square test, b: fisher’s exact test. Abbreviations: NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous cells of unknown significance; ASCH, atypical squamous cells cannot exclude HSIL; LSIL, low-grade intraepithelial lesion; HSIL, high-grade intraepithelial lesion; AIS, adenocarcinoma in situ; SCC, Squamous cell carcinoma Table 5Distribution of cervical cytological results in the two groups (n = 238)CytologyTotal,n (%)HIV-positive,n (%)HIV-negative,n (%)χ2p-valueNILM87(36.6)29(25.4)58(46.8)11.658 < 0.001 a ASCUS52(21.8)26(22.8)26(21.0)0.1180.732aASCH6(2.5)3(2.6)3(2.4)0.0001.000aLSIL37(15.5)17(14.9)20(16.1)0.0670.796aHSIL47(19.7)31(27.2)16(12.9)7.653 0.006 a AIS1(0.4)01(0.8)-1.000bSCC8(3.4)8(7.0)0- 0.002 b a: Pearson’s chi-square test, b: fisher’s exact test. Abbreviations: NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous cells of unknown significance; ASCH, atypical squamous cells cannot exclude HSIL; LSIL, low-grade intraepithelial lesion; HSIL, high-grade intraepithelial lesion; AIS, adenocarcinoma in situ; SCC, Squamous cell carcinoma Distribution of cervical cytological results in the two groups (n = 238) a: Pearson’s chi-square test, b: fisher’s exact test. Abbreviations: NILM, negative for intraepithelial lesion or malignancy; ASCUS, atypical squamous cells of unknown significance; ASCH, atypical squamous cells cannot exclude HSIL; LSIL, low-grade intraepithelial lesion; HSIL, high-grade intraepithelial lesion; AIS, adenocarcinoma in situ; SCC, Squamous cell carcinoma Independent risk factors for cervical cytological abnormalities in the HIV-positive group Multivariate logistic regression analysis was performed to identify risk factors for cervical cytological abnormalities (NILM as the reference group) in the HIV-positive group, with covariates including age, marital status, menopause, parity, CD4 + T cell count, HIV RNA load, ART status, and multiple HR-HPV infection. The results showed that HIV RNA load > 1000 copies/µl was the only independent risk factor for cervical cytological abnormalities (OR = 9.845, 95% CI: 1.324–73.202, p = 0.026) (Table 6). Age, marital status, parity, menopause status, CD4 + T cell count, ART status, and multiple HR-HPV infection were not significantly associated with cervical cytological abnormalities (all p > 0.05). Table 6Multivariate logistic regression analysis of risk factors for cervical cytological abnormalities in the HIV-positive group (n = 114)CovariatesMultivariate analysisExp(B)OR (95% CI)p-valueAge (Years)< 3030–39≥ 40Parity< 2≥ 2Marital StatusMarriedDivorced/Widow/SingleMenopauseNoYesCD4 + counts (cells/µl)-0.3640.623-1.243-0.300-1.034-0.049–2.7090.095–4.101-0.374–4.133-0.030–3.042-0.223–4.789-0.3240.622-0.722-0.308-0.966< 2001.7810.224–14.1640.585200–500> 5000.879-0.180–4.308-0.874-HIV RNA (copies/µl)< 2020-1000> 1000-2.9319.845-0.217–39.5551.324–73.202-0.416 0.026 Antiretroviral treatmentYes---No5.7520.835–39.6270.076Multiple HR-HPV infectionNo---Yes0.5340.117–2.4320.416OR: odds ratio; 95% CI: 95% confidence interval; ART: antiretroviral therapy; HR-HPV: high-risk HPV; p < 0.05 was considered statistically significant Table 6Multivariate logistic regression analysis of risk factors for cervical cytological abnormalities in the HIV-positive group (n = 114)CovariatesMultivariate analysisExp(B)OR (95% CI)p-valueAge (Years)< 3030–39≥ 40Parity< 2≥ 2Marital StatusMarriedDivorced/Widow/SingleMenopauseNoYesCD4 + counts (cells/µl)-0.3640.623-1.243-0.300-1.034-0.049–2.7090.095–4.101-0.374–4.133-0.030–3.042-0.223–4.789-0.3240.622-0.722-0.308-0.966< 2001.7810.224–14.1640.585200–500> 5000.879-0.180–4.308-0.874-HIV RNA (copies/µl)< 2020-1000> 1000-2.9319.845-0.217–39.5551.324–73.202-0.416 0.026 Antiretroviral treatmentYes---No5.7520.835–39.6270.076Multiple HR-HPV infectionNo---Yes0.5340.117–2.4320.416OR: odds ratio; 95% CI: 95% confidence interval; ART: antiretroviral therapy; HR-HPV: high-risk HPV; p < 0.05 was considered statistically significant Multivariate logistic regression analysis of risk factors for cervical cytological abnormalities in the HIV-positive group (n = 114) Age (Years) < 30 30–39 ≥ 40 Parity < 2 ≥ 2 Marital Status Married Divorced/Widow/Single Menopause No Yes CD4 + counts (cells/µl) - 0.364 0.623 - 1.243 - 0.300 - 1.034 - 0.049–2.709 0.095–4.101 - 0.374–4.133 - 0.030–3.042 - 0.223–4.789 - 0.324 0.622 - 0.722 - 0.308 - 0.966 200–500 > 500 0.879 - 0.180–4.308 - 0.874 - < 20 20-1000 > 1000 - 2.931 9.845 - 0.217–39.555 1.324–73.202 - 0.416 0.026 OR: odds ratio; 95% CI: 95% confidence interval; ART: antiretroviral therapy; HR-HPV: high-risk HPV; p < 0.05 was considered statistically significant Discussion This cross-sectional study compared the differences of HPV genotype distribution and cervical lesions between two groups, and identified the risk factors for cervical dysplasia among women with HIV-HPV co-infection in Shanghai, China. We found that HIV-positive women have a higher burden of HR-HPV infection, more frequent multiple HPV infections, and a significantly higher rate of cervical cytological abnormalities than HIV-negative women. Notably, HIV RNA load > 1000 copies/µl was identified as an independent risk factor for cervical dysplasia in the HIV-positive group, which provides important clinical evidence for the management of HIV-HPV co-infection in women. The HIV-positive group in this study was significantly younger and had a higher proportion of unmarried (divorced/widowed/single) participants than the HIV-negative group. These demographic characteristics are consistent with the known epidemiological profile of HIV-infected populations [16–18]. The top five HR-HPV genotypes in this study were HPV16, HPV52, HPV58, HPV53, and HPV18, which is consistent with the distribution of HPV genotypes in Chinese women with HPV infection [19–21]. This is different from the genotype distribution in Western and African countries, where HPV16 and HPV18 are the dominant genotypes [16, 22], which may be due to differences in ethnicity, geography, sexual behavior, and screening strategies. Notably, HPV33 and HPV66 were significantly more prevalent in the HIV-positive group, which is consistent with previous studies on HIV-HPV co-infection [23–25]. HPV33 and HPV66 belong to the Alpha-papillomaviruses with strong carcinogenic potential [26], and co-infection with HPV33 is associated with increased severity of cervical lesions [27, 28], especially persistent infection with sub-lineage A1 is strongly linked to an elevated risk of CIN2/3 and cervical cancer [29]. In the context of HIV-induced immunosuppression, the clearance ability of the host immune system to HPV33 and HPV66 is significantly reduced, leading to persistent infection and increased risk of cervical lesions. Therefore, HPV33 and HPV66 should be considered key genotypes for cervical cancer screening and prevention in WLHIV. Our study showed that WLHIV had significantly higher rate of multiple HPV infection, especially quadruple or more infections. In this study, HPV52 + HPV58 was the most common multiple infection combination, which is consistent with the high prevalence of these two genotypes in Chinese women [30]. Among HPV-positive women, those living with HIV are two to three times more likely to have multiple HPV infections than their HIV-negative counterparts [5, 31]. Furthermore, multiple HPV infections can prolong the duration of HPV persistence and increase the risk of cervical dysplasia by additive or synergistic effects [32–34]. However, multivariate regression analysis in this study found no significant association between multiple HR-HPV infections and cervical cytological abnormalities, possibly because HIV RNA load, as a more important risk factor, masks the effect of multiple HPV infections. In addition, the small sample size of multiple infection subgroups may also lead to insufficient statistical power. Notably, consistent with previous study [35], the positivity rates of vaccine-type HPV genotypes (2-valent, 4-valent, 9-valent) were all significantly higher in the HIV-positive group, with the 9-valent vaccine covering 87.7% of HPV genotypes in the HIV-positive group. This finding indicates that the 9-valent HPV vaccine has a higher coverage rate for HPV infections in WLHIV in China and is more suitable for this population. WHO recommends prioritizing HPV vaccination for WLHIV [36], and previous studies have shown that HPV vaccines can induce high levels of type-specific antibodies in WLHIV with good immunogenicity and safety [37]. In South Africa, HPV vaccination has been proven to be a cost-effective strategy for preventing cervical cancer in WLHIV [38, 39]. Therefore, HPV vaccination, especially with the 9-valent vaccine, should be actively promoted for WLHIV in China to reduce the risk of HPV infection and cervical lesions. In this study, the HIV-positive group had a significantly higher rate of cervical cytological abnormalities (74.6%) than the HIV-negative group (53.2%), including a higher rate of HSIL and all cases of SCC, indicating that HIV infection accelerates the progression of cervical lesions [14, 40]. Multivariate regression analysis identified HIV RNA load > 1000 copies/µl as an independent risk factor for cervical dysplasia, which is consistent with previous studies [41–43]. HIV RNA with high level indicates that the HIV is actively replicating within the body. Prolonged high viral load can lead the body into a state of immunodeficiency, creating more favorable conditions for persistent HPV infection and carcinogenesis, thereby increasing the risk of opportunistic infections and malignancies. Although CD4 + T cell count is an important indicator of immune function in HIV-infected individuals, this study found no significant association between CD4 + T cell count and cervical cytological abnormalities, this may be explained by the limitations of ART in immune reconstitution that not all patients reconstitute CD4 + T cells at the same rate or to the same extent in response to ART, even those with a robust CD4 cell response may remain different degrees of local and systemic immunosuppression [44]. Several studies have shown that mucosal CD4 + cells are destroyed early in HIV infection and do not significantly recover with ART, despite increased circulating CD4 count, indicating the local effects of immune surveillance are uncertain [45, 46]. Previous meta-analyses have revealed that ART showed a trend toward reducing the risk of cervical abnormalities [47, 48], but the difference was not statistically significant in this study, possibly due to the small sample size and differences in ART adherence and duration among participants. Early ART initiation and sustained adherence is important to maintain viral suppression, thus reduce the incidence and progression of SIL and CIN and ultimately incidence of invasive cervical cancer. This study has several limitations. First, it is a single-center cross-sectional study based on retrospective data, with potential selection bias and limited generalizability. Multicenter prospective cohort studies are warranted for external validation. Second, the lack of longitudinal follow-up data precludes dynamic observation of HPV clearance, HIV RNA load changes, and the progression of cervical lesions. Third, 20.2% of HIV RNA data were missing, we applied multiple imputation to handle missing values, yet potential residual confounding from non-random missingness cannot be fully excluded. Conclusions In conclusion, our findings demonstrate that among HPV-positive women, HIV-HPV co-infected individuals present higher rates of multiple HPV infection and cervical cytological abnormalities, elevated HIV RNA load is an independent risk factor for cervical dysplasia in this population. Clinical strategies including timely ART initiation, prioritized 9-valent HPV vaccination, and regular cervical screening should be implemented to reduce cervical lesion and cancer burden in this high-risk population.